1. Volume 19, Issue 6, Pages 852-860 (September 2016)
Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database 
Kathy L. Schulman, MA, Lois E. Lamerato, PhD, Mehul R. Dalal, PhD, Jennifer Sung, PharmD, MS, Mehul Jhaveri, PharmD, Andrew Koren, MD, Usha G. Mallya, PhD, JoAnne M. Foody, MD 
Value in Health 
Volume 19, Issue 6, Pages (September 2016)
DOI: /j.jval
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Patient disposition. CV, cardiovascular risk; HAP, Health Alliance Plan. *High-intensity statin: atorvastatin 40 or 80 mg; rosuvastatin 10, 20, or 40 mg; and simvastatin 80 mg. †Patients were selected randomly to preserve the 80/20 split between moderate- to low-intensity and high-intensity statin patients observed in the administrative database, with 40% on simvastatin, 40% on atorvastatin, and 20% on other statins. ‡Ten patients were excluded because of data quality issues. §Patients with a diagnosis of diabetes, coronary heart disease, or peripheral artery disease in the 12 mo before the qualifying event.
Value in Health  , DOI: ( /j.jval )
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions